Pharmaceutical trademark similarity and balance of convenience led to vacation of an ex parte interim injunction.

In an interlocutory trademark dispute involving pharmaceutical products, prima facie deceptive similarity was assessed with heightened caution because confusion can affect health. Although the marks "LOPARIN" and "LOPRIN" showed some phonetic and visual resemblance, the products differed materially in nature, administration, packaging, price, and therapeutic use, with one being an oral preventive tablet and the other an injectable critical-care medicine. The court also considered delay, alleged acquiescence, and the defendants' established sales and market presence, and found the balance of convenience supported the defendants. The ex parte interim injunction was vacated, and continued restraint was declined, subject to yearly sales statements.

---

---

Issues: Whether the ex parte interim injunction restraining use of the mark "LOPARIN" should continue or be vacated, in view of the alleged deceptive similarity with the mark "LOPRIN", the nature of the competing pharmaceutical products, and the balance of convenience.

Analysis: The competing marks were considered in the context of pharmaceutical goods, where a stricter standard applies because confusion may affect health. Although there was some phonetic and visual resemblance, the products were materially different in nature, mode of administration, packaging, price, and therapeutic use: one was an oral preventive tablet, while the other was an injectable critical-care medicine. The adoption of the mark by the defendants was not found to be demonstrably dishonest at this stage. Delay and alleged acquiescence were weighed, but the defendants had already built up significant sales and market presence. On an interlocutory application, the court confined itself to a prima facie assessment and found the defendants' factual distinctions relevant to both deception and convenience.

Conclusion: The ex parte injunction was vacated, and the interim relief was declined to be continued against the defendants, subject to the defendants filing yearly sales statements of the impugned product.

Ratio Decidendi: In an interlocutory trademark dispute concerning medicinal products, prima facie deceptive similarity must be assessed along with the nature of the goods, mode of use, and balance of convenience, and substantial functional differences between the competing products may justify vacating an ex parte injunction despite some similarity in the marks.

---